Extending the Span of Time in nAMD and DME Management

Intravitreal anti-vascular endothelial growth factor (VEGF) therapies have significantly enhanced visual and anatomical outcomes for patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). However, real-world outcomes are not always comparable to those demonstrated in pinnacle clinical studies, in part due to treatment burden and lack of patient adherence. Corticosteroids are another effective therapeutic option for those patients with DME, but these agents are often not effectively integrated into clinical management protocols. The continued refinement of treatment protocols with FDA-approved therapies and the integration of novel delivery systems and agents with unique mechanisms of action into practice are means of addressing the treatment burden through extending the interval between dosing schedules while maintaining initial visual acuity gains. In this continuing medical education activity, experts in the field assess new injectable-based protocols that lessen the treatment burden as well as evaluate new surgical interventions and procedures that can optimize the treatment of patients with nAMD and DME.